M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
Manuela Gambella,Paola Omedè,Stefania Oliva,Milena Gilestro,Vittorio Emanuele Muccio,Daniela Drandi,Simone Ferrero,Francesca Patriarca,Carmela Palladino,Maria Teresa Petrucci,Norbert Pescosta,Anna Marina Liberati,Tommaso Caravita,Francesco Di Raimondo,Alberto Rocci,Pellegrino Musto,Mario Boccadoro,Antonio Palumbo +17 more
TL;DR: Lower MRD values, both with MFC and RQ-PCR procedures, predict better outcome suggesting that MRD levels can be modified by maintenance.
Journal ArticleDOI
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos,Pellegrino Musto,Monika Engelhardt,Michel Delforge,Gordon Cook,Francesca Gay,N. W. C. J. van de Donk,Ioannis Ntanasis-Stathopoulos,Annette Juul Vangsted,Christoph Driessen,Fredrik Schjesvold,Claudio Cerchione,Sonja Zweegman,Roman Hájek,Philippe Moreau,Hermann Einsele,Jesús F. San Miguel,Mario Boccadoro,Meletios A. Dimopoulos,Pieter Sonneveld,Heinz Ludwig +20 more
TL;DR: The European Myeloma Network has provided an expert consensus to guide patient management in this era as discussed by the authors , and patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death.
Journal ArticleDOI
A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study
Caitlin Costello,Mario Boccadoro,Saad Z. Usmani,Ajai Chari,Robert M. Rifkin,Rafat Abonour,Jesus G. Berdeja,Gordon Cook,Hartmut Goldschmidt,Roman Hájek,Vania Hungria,Hans C. Lee,Xavier Leleu,Jim Omel,Andrew Spencer,Michael A. Thompson,Jorge Vela-Ojeda,Jeffrey A. Zonder,Noemi Puig,Alfonso Aguarón,Faith E. Davies,Brittany Demers,Kaili Ren,Shawn Yu,Tomas Skacel,Dawn Marie Stull,Evangelos Terpos +26 more
TL;DR: Although there are several mechanisms for bleeding in WM, the systematic approach to evaluate will be key to elucidate the underlying diverse mechanisms and highlight the importance of systematic approach.
Journal ArticleDOI
Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma.
Giuseppe Avvisati,M.T. Petrucci,Alessandro Pulsoni,Maurizio Tribalto,Vito Michele Lauta,Angela Gernone,Mario Boccadoro,Filippo Marmont,Alessandro Pileri,F. Dammacco +9 more
Journal ArticleDOI
Dipyridamole in vitro suppresses the generation of T-cell cytotoxic functions: synergistic activity with cyclosporine.
Massimo Massaia,Alberto Bianchi,Carmela Attisano,Umberto Dianzani,Mario Boccadoro,Alessandro Pileri +5 more
TL;DR: The kinetics of suppression showed that dipyridamole prevented the first step of cytotoxicity, i.e. activation of the lytic program following allogeneic or interleukin‐2 stimulation.